S33084, a novel, potent, selective, and competitive antagonist at dopamine D3-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and l741,626

Journal of Pharmacology and Experimental Therapeutics

Volumn 293, Issue 3, 2000, Pages 1048-1062

  Millan, Mark J ^a,b   Gobert, Alain ^a   Newman Tancredi, Adrian ^a   Lejeune, Françoise ^a   Cussac, Didier ^a   Rivet, Jean Michel ^a   Audinot, Valérie ^a   Dubuffet, Thierry ^a   Lavielle, Gilbert ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^b INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIPROPYLAMINO 1,2,3,4 TETRAHYDRO 6 (4 METHOXYPHENYLSULFONYLMETHYL)NAPHTHALENE; 4 (4 CHLOROPHENYL) 1 (1H INDOL 3 YLMETHYL)PIPERIDIN 4 OL; DOPAMINE 3 RECEPTOR BLOCKING AGENT; MITOGEN ACTIVATED PROTEIN KINASE; N [4 (8 CYANO 1,3A,4,9B TETRAHYDRO 3H-BENZOPYRANO[3,4 C]PYRROLE 2 YL)BUTYL] 4 PHENYLBENZAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; DRUG POTENCY; ELECTROPHYSIOLOGY; MOLECULAR CLONING; MOLECULAR RECOGNITION; NEUROCHEMISTRY; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION;

ANIMALS; BENZOPYRANS; BRAIN; DOPAMINE; DOPAMINE ANTAGONISTS; ENZYME ACTIVATION; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); INDOLES; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; NOREPINEPHRINE; OXAZINES; PIPERIDINES; PYRROLES; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SEROTONIN; SULFONES; TETRAHYDRONAPHTHALENES;

EID: 0034089063     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Adell A and Artigas F (1999) Regulation of the release of 5-hydroxytryptamine in the median raphe nucleus of the rat by catecholamine afferents. Eur J Neurosci 11:2305-2311.
2. 3 receptor antagonists, (+)-S 14297, nafadotride, GR 103,691 and U 99194. J Pharmacol Exp Ther 287:187-197.
3. 3 receptor. Bioorg Med Chem Lett 9:179-184.
4. 2 receptor antagonist L-741,626. Br J Pharmacol 119:1491-1497.
5. 3 receptor. Bioorg Med Chem Lett 7:995-998.
6. 4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests. J Pharmacol Exp Ther 283: 1256-1263.
7. 50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
8. 3 receptors mediate mitogen-activated protein kinase activation via a phosphatidylinositol 3-kinase and an atypical protein kinase C-dependent mechanism. Mol Pharmacol 56:1025-1030.
9. 3 receptors. Naunyn-Schmiedeberg's Arch Pharmacol, in press.
10. 2 receptors. Eur J Pharmacol 394:47-50.
11. 2 receptor-deficient mice exhibit decreased dopamine transporter function but no changes in dopamine release in dorsal striatum. J Neurochem 72:148-156.
12. 3 receptor antagonists. Bioorg Med Chem Lett 9:2059-2064.
13. 3H] spiperone binding. Naunyn-Schmiedeberg's Arch Pharmacol 358:342-350.
14. 3 receptor in the presynaptic regulation of dopamine release but not synthesis. Eur J Pharmacol 308:261-269.
15. 3 (auto) receptors inhibits dopamine release in the frontal cortex of freely moving rats in vivo. J Neurochem 66:2209-2212.
16. 3-autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways. J Pharmacol Exp Ther 275:899-913.
17. 3 receptor: Opposite and synergistic interactions with cyclic AMP. J Neurochem 68:1-9.
18. 3 receptor ligand, (+)-UH 232, is a partial agonist. Eur J Pharmacol 282:R3-R4.
19. 3 receptor antagonist. CNS Drug Rev 4:42-53.
20. 2 dopamine receptors. Br J Pharmacol 121:731-736.
21. 3 receptors. Neuroscience 91:911-924.
22. 2 dopamine-receptor-deficient mice is determined by gene dosage, genetic background, and developmental adaptations. J Neurosci 18:3470-3479.
23. 3 receptor mutant mice. J Neurosci 18:2231-2238.
24. 4 receptor. J Med Chem 39:1941-1942.
25. 3 dopamine receptor inhibits P/Q-type calcium channels and secretory activity in AtT-20 cells. J Neurosci 19:1698-1707.
26. 3 autoreceptors inhibits firing of ventral tegmental dopaminergic neurones in vivo. Eur J Pharmacol 275:R7-R9.
27. 3 dopamine receptor: Neurobiology and potential clinical relevance. Pharmacol Rev 49:231-252.
28. 2 receptor-deficient mice. Brain Res 792:253-262.
29. 4 dopamine receptors couple to a voltage-dependent potassium current in N18TG2 x mesencephalon hybrid cell (MES-23.5) via distinct G Proteins. Synapse 31:108-118.
30. 35S] binding. J Pharmacol Exp Ther 285:119-126.
31. 2 receptor deficient mice. Neuroscience 79:323-327.
32. 1B receptors to G-protein coupling and function in corticolimbic structures in vivo. Neuropsychopharmacology 21:S61-S67.
33. 4 receptors: An in vitro and in vivo comparison to L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo [2,3b]pyridine) and raclopride. J Pharmacol Exp Ther 287: 167-186.
34. 2 receptors elicits prolactin secretion and catalepsy. J Pharmacol Exp Ther 275:885-898.
35. 3-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626. J Pharmacol Exp Ther 293:1063-1073.
36. Missale C, Nash SR, Robinson SW, Jaber M and Caron MG (1998) Dopamine receptors: From structure to function. Physiol Rev 78:189-225.
37. 3 receptor. Bioorg Med Chem Lett 5:219-222.
38. 3 receptor. Bioorg Med Chem Lett 6:403-408.
39. 4.4 receptors: Actions of antiparkinsonian and antipsychotic agents. J Pharmacol Exp Ther 282:181-191.
40. 35S]thio)-triphosphate binding and antibody study. Mol Pharmacol 55:564-574.
41. 2 receptor is antagonized by R(-)-n-propylnorapomorphine, raclopride and phenoxybenzamine. Neuropsychopharmacology 15:54-61.
42. 3 receptor antisense influences dopamine synthesis in rat brain. Neuroreport 6:573-576.
43. Patel J, Trout SJ, Palij P, Whelpton R and Kruk ZL (1994) Biphasic inhibition of dopamine release by 7-OH-DPAT in rat nucleus accumbens: A study using fast cyclic voltametry, in Monitoring Molecules in Neuroscience: Proceedings of the 6th International Conference on In Vivo Methods (Louilhot A, Durkin T, Spampinato U and Cador M eds), pp 95-96, Inserm, Université de Bordeaux II, Bordeaux.
44. 3 receptors. Eur J Pharmacol 366:293-300.
45. + channels (GIRK1) in a Xenopus oocyte expression system: Selective antagonism by L-741,626 and L-745,870 respectively. Neuropharmacology 37:983-987.
46. Pizzi M, Valerio A, Carruba MO, Benarese M, Espositi S, Memo M and Spano PF (1993) Evidence for the existence of two distinct dopamine D-2 receptors in presynaptic nerve terminals from rat corpus striatum. Mol Neuropharmacol 3:83-89.
47. 3 agonist PD 128907. J Pharmacol Exp Ther 278:1355-1366.
48. 2-dopamine receptors modulating noradrenaline release in the rat frontal cortex. Eur J Pharmacol 163:393-395.
49. 3 receptor antagonist, activates locomotion in rodents. J Pharmacol Exp Ther 275:1239-1246.
50. Sokoloff P and Schwartz J-C (1995) Novel dopamine receptors half a decade later. Trends Pharmacol Sci 16:270-275.
51. 3 dopamine receptor mRNA is widely expressed in the human brain. Brain Res 779:58-74.
52. 3 autoreceptors on nigrostriatal neurons analyzed by antisense knockdown in vivo. J Neurosci 17:2519-2530.
53. 3 receptors in Chinese hamster ovary cells. J Pharmacol Exp Ther 290:908-916.
54. 4 dopamine receptors couple to G protein-regulated potassium channels in Xenopus oocytes. Mol Pharmacol 49:656-661.
55. 3 ligands as potential antipsychotic agents. Curr Pharm Design 3:391-404.
56. 3 receptor-selective agonists and antagonists. Synapse 31:210-215.
57. 3 receptor antagonists. Bioorg Med Chem Lett 8:2715-2718.